Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Quent Capital LLC

Quent Capital LLC lessened its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 7.4% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 475 shares of the pharmaceutical company’s stock after selling 38 shares during the period. Quent Capital LLC’s holdings in Vertex Pharmaceuticals were worth $211,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Advisor OS LLC increased its position in Vertex Pharmaceuticals by 4.4% in the 1st quarter. Advisor OS LLC now owns 543 shares of the pharmaceutical company’s stock valued at $263,000 after acquiring an additional 23 shares during the period. Avidian Wealth Enterprises LLC increased its position in Vertex Pharmaceuticals by 2.1% in the 1st quarter. Avidian Wealth Enterprises LLC now owns 1,225 shares of the pharmaceutical company’s stock valued at $594,000 after acquiring an additional 25 shares during the period. Strategic Blueprint LLC increased its position in Vertex Pharmaceuticals by 1.7% in the 1st quarter. Strategic Blueprint LLC now owns 1,498 shares of the pharmaceutical company’s stock valued at $726,000 after acquiring an additional 25 shares during the period. Newman Dignan & Sheerar Inc. increased its position in Vertex Pharmaceuticals by 3.3% in the 2nd quarter. Newman Dignan & Sheerar Inc. now owns 786 shares of the pharmaceutical company’s stock valued at $350,000 after acquiring an additional 25 shares during the period. Finally, Hager Investment Management Services LLC increased its position in Vertex Pharmaceuticals by 0.5% in the 1st quarter. Hager Investment Management Services LLC now owns 5,411 shares of the pharmaceutical company’s stock valued at $2,623,000 after acquiring an additional 27 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

VRTX stock opened at $403.30 on Friday. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $519.88. The stock’s 50 day moving average price is $399.12 and its 200 day moving average price is $442.50. The firm has a market cap of $103.40 billion, a P/E ratio of 28.83 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, beating the consensus estimate of $4.24 by $0.28. The company had revenue of $2.94 billion during the quarter, compared to the consensus estimate of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.Vertex Pharmaceuticals’s revenue was up 11.3% on a year-over-year basis. During the same period in the previous year, the firm posted ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. UBS Group set a $553.00 price objective on Vertex Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 5th. Wall Street Zen lowered Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, August 22nd. Stifel Nicolaus lowered their price objective on Vertex Pharmaceuticals from $494.00 to $455.00 and set a “hold” rating on the stock in a report on Tuesday, August 5th. Truist Financial set a $490.00 price objective on Vertex Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 5th. Finally, Royal Bank Of Canada lowered their price objective on Vertex Pharmaceuticals from $430.00 to $405.00 and set a “sector perform” rating on the stock in a report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $493.81.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs purchased 5,000 shares of the business’s stock in a transaction on Wednesday, August 6th. The stock was bought at an average cost of $389.68 per share, for a total transaction of $1,948,400.00. Following the acquisition, the director owned 45,000 shares of the company’s stock, valued at approximately $17,535,600. The trade was a 12.50% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.